Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors during the central anxious system, conolidine modulates alternate molecular targets. A Science Innovations examine identified that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availab... https://boyst097wae2.shopping-wiki.com/user